Meropenem PK/PD Variability and Renal Function: “We Go Together”
Pharmaceutics · 30.08.2023 · 15 (9) · 2238
DOI: 10.3390/pharmaceutics15092238 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 30.08.2023. Verfasst von Jacopo Angelini und 6 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology and Toxicology Institute, University Hospital Friuli Centrale ASUFC, 33100 Udine, Italy. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Meropenem is a carbapenem antibiotic widely employed for serious bacterial infections. Therapeutic drug monitoring (TDM) is a strategy to optimize dosing, especially in critically ill patients. This study aims to show how TDM influences the management of meropenem in a real-life setting, not limited to intensive care units.
Methods
From December 2021 to February 2022, we retrospectively analyzed 195 meropenem serum concentrations (Css). We characterized patients according to meropenem exposure, focusing on the renal function impact.
Results
A total of 36% (n = 51) of the overall observed patients (n = 144) were in the therapeutic range (8–16 mg/L), whereas 64% (n = 93) required a meropenem dose modification (37 patients (26%) underexposed; 53 (38%) overexposed). We found a strong relationship between renal function and meropenem concentrations (correlation coefficient = −0.7; p-value < 0.001). We observed different dose-normalized meropenem exposure (Css/D) among renal-impaired (severe and moderate), normal, and hyperfiltrating patients, with a median (interquartile range) of 13.1 (10.9–20.2), 7.9 (6.1–9.5), 3.8 (2.6–6.0), and 2.4 (1.6–2.7), respectively (p-value < 0.001).
Conclusions
Meropenem TDM in clinical practice allows modification of dosing in patients inadequately exposed to meropenem to maximize antibiotic efficacy and minimize the risk of antibiotic resistance, especially in renal alterations despite standard dose adaptations.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Clinical Pharmacology and Toxicology Institute, University Hospital Friuli Centrale ASUFC, 33100 Udine, Italy.
- Department of Medicine, University of Udine (UNIUD), 33100 Udine, Italy.
- Infectious Diseases Division, Department of Medicine, University of Udine and Azienda Sanitaria Universitaria Friuli Centrale, 33100 Udine, Italy.
ORCID-Profile: Jacopo Angelini, Alberto Pagotto, Francesco Lo Re, Massimo Baraldo
Zitieren
APA
Angelini, J., Giuliano, S., Flammini, S., Pagotto, A., Lo Re, F., Tascini, C., & Baraldo, M. (2023). Meropenem PK/PD Variability and Renal Function: “We Go Together”. Pharmaceutics, 15(9), 2238. https://doi.org/10.3390/pharmaceutics15092238
Vancouver
Angelini J, Giuliano S, Flammini S, Pagotto A, Lo Re F, Tascini C, et al. Meropenem PK/PD Variability and Renal Function: “We Go Together”. Pharmaceutics. 2023;15(9):2238. doi:10.3390/pharmaceutics15092238
BibTeX
@article{Angelini2023,
author = {Angelini, Jacopo and Giuliano, Simone and Flammini, Sarah and Pagotto, Alberto and Lo Re, Francesco and Tascini, Carlo and Baraldo, Massimo},
title = {Meropenem PK/PD Variability and Renal Function: “We Go Together”},
journal = {Pharmaceutics},
year = {2023},
volume = {15},
number = {9},
pages = {2238},
doi = {10.3390/pharmaceutics15092238}
}
EUVIMED